Arcutis Biotherapeutics Inc (NAS:ARQT)
$ 10.25 -0.59 (-5.44%) Market Cap: 1.20 Bil Enterprise Value: 1.15 Bil PE Ratio: 0 PB Ratio: 7.65 GF Score: 29/100

Arcutis Biotherapeutics Inc Atopic Dermatitis Topline Data Call Transcript

Dec 12, 2022 / 01:30PM GMT
Release Date Price: $16.58 (-2.47%)
Operator

Good day, and thank you for standing by. Welcome to the Arcutis Biotherapeutics top line data call. (Operator Instructions) Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Eric McIntyre, Head of Investor Relations. Please go ahead.

Eric McIntyre
Arcutis Biotherapeutics, Inc. - Head of IR

Thank you, Michelle. Good morning, everyone, and thanks for joining. We are incredibly excited to be here with you again today to discuss pivotal Phase III results from our INTEGUMENT-1 and 2 trials in atopic dermatitis and certainly also proud of the continued execution on the clinical front and progress towards realizing the long-term value for topical roflumilast. A couple of logistical details before we get started. Our Arcutis management team is all here today, and will also be joined by Dr. Larry Eichenfield during our prepared remarks as well as for Q&A.

You could find today's webcast and posted presentation under the Events and Presentations section of our Investor website.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot